News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Where's their company "shill", I forgot his name posted every day saying it's a "great company" blah blah blah bullshot. I think it was one of the owner's kids since he wanted to get into the family scamming business. What a SH*T Show this was. GL
SEC CHARGES QNTA EXECS WITH FRAUD !!! I saw that “maintenance mode” for MedolifeRx. I’m assuming ((?) hopeful anyways)) that they are working on the verbiage changes the fda is demanding, and working toward putting it back online
For reference sake - In the meantime I checked and The Aelia page is still accessible online https://aeliastore.com/
And muscle rub still found on Amazon too
I tried to tell uh...ummm..... "Grant" that I was "working this case" and that "THE SEC" was gonna bust the Mooooochelian crime clan and bust um hard LMAO - some kids never listen :)))
https://www.sec.gov/litigation/litreleases/lr-25726
QUOTE:
LITIGATION RELEASES
Quanta, Inc.
SEC Charges Microcap Company and Its Executives with Fraud
Litigation Release No. 25726 / May 15, 2023
Securities and Exchange Commission v. Quanta, Inc., et al.;, ivil Action No. 2:23-cv-03683 (C.D. Cal. filed May 15, 2023)
The Securities and Exchange Commission today announced that Quanta, Inc., a Burbank, California-based biopharmaceutical company that develops and sells a scorpion venom product called Escozine, its CEO, Arthur Mikaelian, and his son and Quanta's executive vice president in charge of operations, Grant Mikaelian, have agreed to settle fraud charges without admitting or denying the allegations in the SEC's complaint. As part of the settlement, the Mikaelians consented to officer and director bars and to pay civil penalties.
According to the SEC's complaint, in a July 23, 2021 press release, Quanta and Arthur Mikaelian misrepresented the FDA staff's response to the company's proposed clinical trial of Escozine as a Covid-19 treatment.
As the complaint alleges, the press release misrepresented that the FDA staff's response validated the clinical study conducted in the Dominican Republic and that the FDA's staff had recognized the potential therapeutic benefits of Escozine. The complaint further alleges that these, and additional false and misleading statements in the press release, gave investors the impression that the FDA's staff was positive about the proposed clinical trial and the results of its clinical trials in the Dominican Republic.
However, as alleged in the complaint, the FDA staff's response stated that the Dominican Republic clinical trial "cannot be directly leveraged to support your proposed clinical trial" and that antiviral activity "has not been demonstrated with your specific product, Escozine."
In addition, the SEC's complaint alleges that Quanta included $198,000 of improperly recognized revenue in its Form 10-Q for the first quarter of 2021, causing Quanta to overstate its total revenue by 61% in that quarter.
The SEC's complaint alleges that Quanta based its improper revenue recognition on a backdated purchase order created by Grant Mikaelian for its Escozine immunapens, which it also provided to Quanta's auditors as support for its revenues. The SEC's complaint further alleges that Arthur Mikaelian falsely represented in a management representation letter to Quanta's auditor that the quarterly financials were prepared in accordance with generally accepted accounting principles (GAAP), and he certified Quanta's first quarter Form 10-Q, which included the $198,000 in revenue.
Quanta, without admitting or denying the allegations in the SEC's complaint, consented, pre-filing, to the entry of a final judgment which permanently enjoins it from violating the antifraud, reporting, books and records, and internal controls provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Sections 10(b), 13(a), 13(b)(2)(A) and 13(b)(2)(B) of the Securities Exchange Act of 1934 ("Exchange Act") and Rules 10b-5, 12b-20, 13a-1, and 13a-13 thereunder.
Arthur and Grant Mikaelian, without admitting or denying the allegations in the SEC's complaint, consented, pre-filing, to the entry of final judgments permanently enjoining each of them from violating Section 17(a) of the Securities Act and Sections 10(b) and 13(b)(5) of the Exchange Act and Rules 10b-5, 13a-14, 13b2-1, and 13b2-2 thereunder, and from aiding and abetting violations of Sections 13(a), 13(b)(2)(A), and 13(b)(2)(B) of the Exchange Act and Rules 12b-20, 13a-1, and 13a-13 thereunder and Rules 12b-20 and 13a-13 thereunder, respectively. In addition, Arthur and Grant Mikaelian each consented, pre-filing, to five-year officer and director bars and five-year penny stock bars, and civil penalties of $150,000 and $75,000, respectively.
The SEC's investigation was conducted by Junling Ma and Lorraine Pearson under the supervision of Victoria Levin and Rhoda Chang, with the assistance of trial counsel Donald Searles under the supervision of Gary Leung. The SEC appreciates the assistance provided by the U.S. Food and Drug Administration (FDA) and the Financial Industry Regulatory Authority.
DIRTY father creates DIRTY POS son - two DIRTY common criminal peas in a DIRTY POD....ANY questions now as to WHY THIS CRIME TICKER WAS REVOKED and ain't NEVER ever ever coming back....let alone the JOKE of their "on line" bullshit "store" blah blah LMAO WTF ?????
THEE END of the "civil" portion and now the CRIMINAL DOJ INDICTMENTS will follow......and WELCOME TO CLUB FED and SOAP ON A ROPE ole MOOCHELIAN CLAN-FAM scammers LMAO !!!
SHOUT-OUT TO DUMB ASS TONY FOR PUMPING THIS DOG SHIT SCAM.....GO TONY....:))))
AND and and NEVER forget the BIG LEBOWSKI ASS CLOWN on the "conference call" where that jack wad was kicking back on the couch and spewing about boozing and hookers in Vegas and the ole MOOCH aka DIRTY ARTHUR had to spank that ass clown, "HEY - WE ARE STREAMING LIVE YOU IDIOT" Bwaaaa ha ha ha .... I KNEW then and there I had "the bust" on these 2-bit cons.... in the bag !!!!
QUANTA-CON: FDA WARNING LETTER = THEE END :))
I personally had written the FDA multiple "EXTENSIVE "briefs" (and the FTC also) on ALL the fraudulent claims, safety issues, illegal "new drug claims" etc being made about Escozine.
I noted that per FDA LAW "ESCOZINE" aka SNAKE OIL INC aka QUANT-aCON... would be a "Misbranded or adulterated" and/or "Non FDA APPROVED NEW DRUG" (NO IRB or prior FDA approval(s) etc) .....which are federal crimes !!
I 100% KNEW this was a crime scene when the MOOCH and crew "tried" to peddle the "PRE IND" utter bullshit and I posted extensively about such fraudulent claims !!
NO SUCH THING as a "PRE IND NUMBER" blah blah exists - I have extensive FDA drug approval and regulatory compliance experience and KNEW their claims were utter and total bullshit and in fact VERY MUCH ILLEGAL.....thus....THE FDA "FORMAL WARNING LETTER" which is a very very very serious warning...one issued PRIOR to a potential FDA civil lawsuit and/or a FDA-DOJ criminal lawsuit.....they're not jacking around here folks in this warning letter...
SELLING and using INTERSTATE COMMERCE TO "PRODUCE/MOVE/SELL" what is an ILLEGAL DRUG and/or a misbranded and/or "adulterated" drug as defined by the FDA...and doing so ON USA soil is a federal crime...as in FEDERAL BIG BOY KINDA CRIME no different than selling illegal narcotics etc....
The FDA took action which is partially why "THE SEC" and "OTC MARKETS" were also told via federal agency inter-communication to REVOKE THIS SCAM and FRAUD TICKER and to pursue THE MOOCH and his PUNK ASS FRAUD KID -
The MOOCH and his punk kid can STILL face potential criminal and/or civil regulatory sanctions, fines and even arrest for illegally selling "NON APPROVED DRUGS" on USA soil.....we shall see.....
Here's what was the FINAL BLOW to ending this con-job and literal crime scene folks :
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medolife-rx-dba-medolife-corp-aelia-inc-and-quanta-inc-651522-04192023
QUOTE:
"WARNING LETTER
April 19, 2023
RE: 651522
"
THEY HAD 15 DAYS TO "COMPLY" or face civil regulatory fines, injunction etc.
It is MAY 19 2023 and THE WEBSITE(s) PEDDLING THIS CRAP ARE STILL UP =
https://aeliastore.com/shop/
https://www.youtube.com/watch?v=GSmxL9L6L1k
Couldn't have said it any better. 
QNTA-FRAUD: SEC CRIME SCENE REVOKED !! QNTA: SEC Registration(s) revoked:
I TRIED TO WARN folks what was coming.....!!
RIP QNTA-FRAUD 2023....LAST RIGHTS....THIS DEAD HORSE CON-JOB HAS BEEN SENT TO THE GLUE FACTORY :))
Boys n girls - I TRIED to warn the penny marks on this one that it was a total CRIME SCENE and literal gutter fraud ......
https://www.sec.gov/litigation/admin/2023/34-97503.pdf
https://www.sec.gov/litigation/admin/2023/34-97503.pdf
The MOOCH and his punk KID WILL BE INDICTED which I prior "predicted" also - it's cast in stone that they will face criminal SECURITY'S FRAUD charges among "other" potential civil and criminal penalties to be levied.....
This ticker is now OFFICIALLY DEAD and worth absolutely NOTHING aka $ZERO per share.....one can "TRY" to get their broker to work with them to get a "DEAD TICKER CERT" and see if they can somehow generate a 1099 TOTAL LOSS for tax purposes..
ALL THAT IS LEFT IS TO "TRY" and harvest a capital gains tax loss for annual deduction and/or to potentially off-set some unforseen capital gain.
GOOD LUCK and GOOD NIGHT - this crime scene is now CLOSED PERMANENTLY :))
Arthur's behavior demonstrates a tertiary stage syphilis case.
There is an addiction worse than drugs: The Mamasitas Chapiadoras From DR that Mikaelian has been hitting hard. Those Chapiadoras are professional G-Diggers, might explain how this lucrative business destroyed so easily. Sad ending, I only hope Karma gives him a small lesson on not to spend other people hard worked money on Chapiadoras. Viva the Scorpion Venom
Is Grant Mikaelian a drug addict?...Would explain...fraud...non-performance.
They obviously won't ever do anything constructive that will benefit anyone but themselves. Stole everyone's money, hiding, bullshitting shareholders is all I've heard.
Grant Moochaelian is a sleezy lowlife POS with no conscience whatsoever. There is no other way to describe his continued raping of shareholders. This scum couldn't manage to install a roll of toilet paper in a dispenser and yet pretends to be a VP for Daddy's company.
Thieving Moochaelians hiding are not down!! Shareholders are!!
HOWEVER they while they are down, they aren’t completely out
Perseverance in securities fraud? What lowlife criminal scum!!!!
Hopefully, the lesson is perseverance pays off … they have definitely struggled - HOWEVER they while they are down, they aren’t completely out … as noted in their Dec PR they anticipated resuming shipping of the immunipen AND have done exactly that … products ARE being delivered and work as described… let’s hope continues perseverance in spite of all the obstacles they persevere.. also if they pull a rabbit out of the hat so to speak then we ALL win 
GLTA
|
Followers
|
116
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
13741
|
|
Created
|
03/12/18
|
Type
|
Free
|
| Moderators | |||
Quanta for 2021 will be undergoing a name change to be announced shortly as well as Quanta is in the process of expanding its product line from 4 SKUs to 38 by summer. We will also be introducing all new branding with new color schemes, new packaging, and exciting celebrity endorsements for the pain relief products and a newly introduced beauty product line. Quanta will also be working on a men’s cosmetic line in conjunction with one of the celebrity endorsements planned for late 2021. The company has hired an advertising agency to help with the rollout of the new branding expected second quarter 2021. This will work in conjunction with a major push the company is on the path of with some major big box retail chains.
Quanta Basics
Quanta is a cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption.
The established resonance theory behind Quanta’s polarization process has many potential applications. From potentiating bio-ingredients to produce more-effective carbon-trapping plants to transformative anti-aging solutions Quanta’s technology has the opportunity to upend how commercial products are made and the benefits from them. Already we see multi-trillion-dollar global industries benefiting from Quanta’s technology.
Our proof of concept, Quanta’s market-leading CBD pain-relief rub (“Muscle Rub”), is only the first in a series of paradigm shift products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized active ingredient is more soluble and creates stronger bonds with the body’s receptors. This allows us to enhance ingredients so they work faster and more powerfully without the use of chemical by-products or cellular penetration. Quanta believes this natural solution has nearly limitless applications in the world of plant-based consumer products.
Quanta is involved in ambitious projects that we believe will reshape the next wave of climate science, sustainability, nutrition, and more. Having harnessed the technology of the future, Quanta is dedicated to bringing tomorrow’s health and wellness solutions to the billions in need today.
Discovery Synopsys
Using our product development process and business-to-business and direct-to-consumer sales approaches as a benchmark for future business, we developed the Quanta business model. Our technology’s unique ability to strengthen ingredients renders them more potent without added chemicals or penetrating cells means Quanta is in a first-of-its-kind position in the market. As the world’s first company focused on Quantum Biology we sit in a strong, but unique position in the market.
Our ability to increase ingredient efficacy by up to 500% means we are in a rare position to truly disrupt many areas of material science.
Quanta’s technology renders products superior to any on the market today. A 30% re-purchase rate (on one SKU alone) illustrates consumer appetite for the product.
Upcoming products and ventures will be designed to achieve or surpass this level of consumer benefit and uptake.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1691430/000149315221008846/form10-k.htm
Management Team
Arthur Mikaelian, Ph.D.
Chairman & CEO
One of Dr. Arthur Mikaelian’s greatest scientific contributions and groundbreaking inventions is Quantum Physics and Quantum Biology-based polarization technology, which targets molecular structure of the main ingredients in synthetic medications or natural compounds, leading to the increased potency of liquid and solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284B2 as it pertains to the Polarized Scorpion Venom solution. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), and the master gene’s (ATF3) indirect influence on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of pharmaceutical and nutraceuticals drugs, as well as expanding his interests in cancer and oncology.
Dr. Mikaelian’s education began in 1984 at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological/NeuroPsychology; he then went on to complete his postdoctoral work at Vernadsky. Dr. Mikaelian has broad experience with Quantum Physic and Quantum Biology. He also earned an MBA from the University of Bologna in Italy.
Khalid Matalka, Ph.D., SI(ASCP)
Chief Scientific Officer
Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992. After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.
Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory. During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist. While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.
Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals. Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.
Grant Mikaelian
Executive Vice President
In 2013, Mr. Grant Mikaelian began working for an advanced biopharmaceutical company called Medolife. During his employment, he amassed a wide range of skills through managing various departments of the company. As a Marketing Sales Department Manager, he led many successful projects to improve customer experience through website development and design, enhanced customer support, streamlined ordering systems, configuration of B2C/B2B logistics, company rebranding, and preparation of marketing literature and presentations. He was later promoted to Operations Manager, overseeing and optimizing company departments on a larger scale. He was involved in production planning, project management of short and long-term goals, hiring prospective employees and contractors, corporate IT improvements, equipment procurement, international product registrations, due diligence preparation, and financial audits. He came to inspire confidence and began working closely with Dr. Arthur Mikaelian, CEO of Medolife. Soon after, Mr. Mikaelian was further promoted to Chief Business Development Officer. As the CBDO, he worked with existing and potential shareholders, was involved in domestic and international investment opportunities, managed multiple departments, increased company and product awareness, expanded product distribution channels, drafted Press Releases and articles, edited and proofread company literature, and more. Mr. Mikaelian is an organized leader with broad experiences in management and promotion of corporate growth.
Clemente Pascarella
Audit Committee
Christopher Rullan
Attorney for Mexico Division
Eduard Sahakyan
Head of R&D
Dr. Sahakyan started his career at Glendale Community College (GGC) as a lab technician for the biology department. He then pursued a biotechnology major at Pasadena City College (PCC). During his studies he interned at the Pasadena Bio Collaborative (PBC) Incubator as part of the LA Bioscience Hub research outreach program. Dr. Sahakyan worked with multiple companies including UCLA, Amgen and others during his summer internship. Upon completion, he was offered a permanent position at BCN (UCLA research collaborative) where he completed multiple projects, some of them are pending publication. In 2019, Dr. Sahakyan was offered a position in Medolife as a research associate. Within a year he was promoted to head scientist. Throughout this time, Dr. Sahakyan has worked on a number of company projects, which he presented at different local and national conferences. One of his bigger projects is the differentiation of embryonic stem cells into red blood cells. He continuously brings new ideas and initiatives to the company.
